Sanofi-Aventis (NYSE: SNY) unveiled a further push into emerging markets with plans to buy Polish consumer healthcare group Nepentes in a deal valuing it at around 105 million euros ($130.4 million). Release | Report
Companies are losing clients and compromising their global clinical trials because the worldwide telephone numbers assigned to these trials are flawed. Participants and doctors calling to report critical trial data often cannot due to non-operational telephone numbers. To learn more visit our website http://www.fiercebiotech.com/offer/clinicaltrial_telephone.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 90,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!